Procter & Gamble Health
5,305.00
+2.00(+0.04%)
Market Cap₹8,806.00 Cr
PE Ratio28.68
IndustryHealthcare
Company Performance:
1D+0.04%
1M-7.30%
6M-14.67%
1Y-1.65%
5Y-25.75%
View Company Insightsright
More news about Procter & Gamble Health
30Jul 25
P&G Hygiene Shares Surge as Quarterly Profit Doubles to ₹192 Crore
Procter & Gamble Health reported impressive Q2 results with net profit doubling to ₹192.00 crore from ₹81.00 crore year-over-year. Revenue marginally increased by 0.6% to ₹937.00 crore. EBITDA rose significantly to ₹266.00 crore, with EBITDA margin expanding to 28.4% from 12.7%. The stock price surged, reaching an intraday high of ₹14,540.00 (11.06% increase). Management attributed the strong performance to successful execution of their integrated growth strategy focusing on daily use categories and product superiority.
 no imag found
30May 25
Procter & Gamble Health Reports Q4 Profit Surge and Announces Dividend
Procter & Gamble Health's Q4 net profit rose 31.4% year-over-year to ₹612.00 million, while revenue increased 23% to ₹3.10 billion. However, net profit decreased 32.7% quarter-over-quarter. The company's board recommended a dividend of ₹45.00 per equity share.
 no imag found
29May 25
Procter & Gamble Health: Q3 Profit Surges 31%, ₹45 Dividend Proposed
Procter & Gamble Health announced impressive Q3 financial results. Net profit increased by 31.30% to ₹61.20 crore, while revenue grew by 23.20% to ₹311.00 crore. EBITDA rose by 20.20% to ₹81.00 crore. The company's board recommended a dividend of ₹45.00 per equity share. For the nine-month period, sales increased by 8.00% to ₹918.00 crore, and Profit After Tax grew by 27.00% to ₹234.00 crore.
 no imag found
28May 25
P&G India Misses Q3 Expectations, Long-Term Growth Remains Steady
Procter & Gamble Hygiene and Health Care Ltd (P&G India) reported disappointing Q3 results, falling short of market expectations. However, the company's long-term growth trajectory remains positive. P&G India has maintained a consistent revenue CAGR of 7.00% from FY19 to FY24, expected to continue through FY27E. Despite quarterly inconsistencies, annual performance shows steady growth. The company has improved its EBITDA margin by 250 basis points to approximately 23.50% over the FY19-FY24 period.
 no imag found
Procter & Gamble Health
5,305.00
+2.00
(+0.04%)
1 Year Returns:-1.65%
Industry Peers
Sun Pharmaceutical
1,610.10
(+0.93%)
Divis Laboratories
6,056.00
(+0.08%)
Torrent Pharmaceuticals
3,997.10
(+0.92%)
Cipla
1,328.90
(+0.37%)
Dr Reddys Laboratories
1,178.70
(-3.23%)
Lupin
2,135.20
(-0.82%)
Zydus Life Science
878.10
(-0.81%)
Mankind Pharma
2,093.90
(-1.42%)
Aurobindo Pharma
1,172.10
(-2.95%)
Alkem Laboratories
5,565.00
(-1.98%)